PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B
Chronic hepatitis B (CHB) affects 260 million people worldwide. Despite advances in antiviral therapies, functional cure, characterized by sustained loss of hepatitis B surface antigen (HBsAg) and durable viral control after treatment cessation, remains infrequent. The PD-1/PD-L1 immune checkpoint p...
Shranjeno v:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2026-07-01
|
| Serija: | Frontiers in Immunology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1831739/full |
| Oznake: |
Brez oznak, prvi označite!
|